Tucatinib,Trastuzumab,fulvestrant
Seagen
['bcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'crcsm', 'tucatinib']
moving to #precisionmedicine. #her2 in cholangiocarcinoma - biliary tract cancers . tucatinib trastuzumab
already approved in #bcsm #crcsm. #asco23 the next agnostic marker. 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23